Intellectual Property

We protect our product candidates through the use of patents, trade secrets and careful monitoring of our proprietary know-how. Our patent portfolio is wholly owned by us and includes issued patents and patent applications that claim deuterated analogs of a number of non-deuterated drugs and drug candidates.

The U.S. Patent and Trademark Office (USPTO) has issued Concert over 100 patents. Additionally, our patent portfolio includes numerous issued foreign patents, including issuances in Europe, Japan, China, Australia and Russia, among other territories.

To learn more about Concert’s U.S. issued patents visit the USPTO website.

IPR Proceeding

In April 2018, the Patent Trial and Appeal Board (PTAB) of the USPTO instituted an Inter Partes Review (IPR) proceeding brought by Incyte seeking to invalidate Concert’s U.S. Patent No. 9,249,149. In April 2019, the PTAB issued a final written decision in connection with the IPR that held that the claims of the ‘149 patent were unpatentable as obvious. Concert has appealed the final written decision to the Federal Circuit. Concert remains committed to defending the ‘149 patent, which remains valid and enforceable until any appeals by us have been exhausted.

Copies of certain documents relating to the Federal Circuit IPR appeal follow below:

Copies of certain documents relating to the PTAB IPR proceeding follow below:

PGR Proceeding

In May 2021, the PTAB instituted a Post Grant Review (PGR) proceeding brought by Incyte seeking to invalidate Concert’s U.S. Patent No. 10,561,659. In May 2022, the PTAB issued a final written decision in connection with the PGR upholding the validity of all of the challenged claims.

Copies of certain documents relating to the PGR follow below: